[Ip-health] Ruling threatens to upend patents on Moderna’s Covid-19 vaccine

James Love james.love at keionline.org
Fri Jul 24 05:05:13 PDT 2020

This won't be the last of the disputes over vaccine patent landscapes.



By DAMIAN GARDE @damiangardeJULY 23, 2020

The U.S. Patent and Trademark Office denied Moderna’s claim that a patent
held by a rival company was invalid. The patent, which covers technology
used to deliver messenger RNA treatments, is held by the Canadian firm

That sets up a situation in which Arbutus might file for an injunction
that, if successful, would block Moderna from selling its Covid-19 vaccine,
which is expected to enter a Phase 3 trial this month. It might also lead
Moderna to negotiate a license agreement in exchange for royalties, which,
if the company’s vaccine becomes the multibillion-dollar product Wall
Street expects, could bring in hundreds of millions of dollars for Arbutus.

Moderna’s share price fell about 10% on the news Thursday, losing roughly
$3 billion in value. Arbutus, a small-cap company, nearly doubled.

. . . .

More information about the Ip-health mailing list